130 related articles for article (PubMed ID: 36720212)
1. The Effects of Treatment Regimen on the Initial Management of Macular Neovascularization Subtypes in Age-Related Macular Degeneration.
Kodaday K; Kodjikian L; Gadiollet E; Chirpaz N; Loria O; Feldman A; De Bats F; Burillon C; Denis P; Pradat P; Mathis T
Ophthalmologica; 2023; 246(2):113-122. PubMed ID: 36720212
[TBL] [Abstract][Full Text] [Related]
2. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
[TBL] [Abstract][Full Text] [Related]
3. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
[TBL] [Abstract][Full Text] [Related]
4. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
5. Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients.
Kim KT; Chae JB; Lee S; Seo EJ; Kim DY
BMC Ophthalmol; 2021 Aug; 21(1):294. PubMed ID: 34376158
[TBL] [Abstract][Full Text] [Related]
6. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
7. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
9. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
10. Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.
Kim JH; Kim JW; Kim CG
J Ocul Pharmacol Ther; 2022 Apr; 38(3):261-268. PubMed ID: 35119292
[No Abstract] [Full Text] [Related]
11. [Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration].
Fursova AZ; Nikulich IF; Dmitrieva EI; Gusarevich OG; Derbeneva AS; Vasilyeva MA; Kozhevnikova OS; Kolosova NG; Rabota FK
Vestn Oftalmol; 2023; 139(6):50-58. PubMed ID: 38235630
[TBL] [Abstract][Full Text] [Related]
12. Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration.
Kato A; Yasukawa T; Sugita I; Yoshida M; Nozaki M; Hirano Y; Kondo J; Abe T; Sugita K; Okita T; Morita H; Takase N; Ogura Y
Adv Ther; 2022 Mar; 39(3):1403-1416. PubMed ID: 35112307
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
14. Results of Switching from Pro Re Nata to Treat-and-Extend Regimen in Treatment of Patients with Type 3 Neovascularization.
Kim JH
Semin Ophthalmol; 2020 Jan; 35(1):33-40. PubMed ID: 31814497
[No Abstract] [Full Text] [Related]
15. Volume-rendering three-dimensional image analysis of macular neovascularization in age-related macular degeneration.
Choi M; Han S; Kim SW; Yun C; Oh J
Eye (Lond); 2024 Apr; 38(6):1125-1132. PubMed ID: 38040962
[TBL] [Abstract][Full Text] [Related]
16. Morphological changes of macular neovascularization during long-term anti-VEGF-therapy in neovascular age-related macular degeneration.
Pauleikhoff D; Gunnemann ML; Ziegler M; Heimes-Bussmann B; Bormann E; Bachmeier I; Yu S; Garcia Armendariz B; Pauleikhoff L
PLoS One; 2023; 18(12):e0288861. PubMed ID: 38134207
[TBL] [Abstract][Full Text] [Related]
17. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration.
Hatz K; Prünte C
Br J Ophthalmol; 2016 Oct; 100(10):1341-5. PubMed ID: 26755642
[TBL] [Abstract][Full Text] [Related]
18. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
Aurell S; Sjövall K; Paul A; Morén Å; Granstam E
Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
[TBL] [Abstract][Full Text] [Related]
19. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
20. Incidence and multimodal imaging characteristics of macular neovascularisation subtypes in Chinese neovascular age-related macular degeneration patients.
Zhang Y; Gan Y; Zeng Y; Zhuang X; Zhang X; Ji Y; Su Y; Wen F
Br J Ophthalmol; 2024 Feb; 108(3):391-397. PubMed ID: 36639223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
